chellenberg Wittmer advised Santhera Pharmaceuticals on the deal. Swiss Biotech Santhera has entered an exclusive licence agreement with China-based Sperogenix Therapeutics for the development of Vamorolone...
This content is for Standard 1 Year members only. LoginJoin Now